Overview

A Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2031-03-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to find out if the experimental product, axi-cel, is safe and effective in treating your lymphoma, compared to standard of care (SOC) therapy chemotherapy), which includes either R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab).

Phase:

Phase 3

Details

Lead Sponsor:

Kite, A Gilead Company

Treatments:

Cyclophosphamide
Doxorubicin
Etoposide
Fludarabine
Prednisone
Rituximab
Vincristine